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Background. An 18-month-old boy developed encephalopathy, for which extensive investigation failed to iden-
tify an etiology, 6 weeks after stem cell transplant. To exclude a potential infectious cause, we performed high-
throughput RNA sequencing on brain biopsy.
Methods. RNA-Seq was performed on an Illumina Miseq, generating 20 million paired-end reads. Nonhost data
were checked for similarity to known organisms using BLASTx. The full viral genomewas sequenced by primer walking.
Results. We identiﬁed an astrovirus, HAstV-VA1/HMO-C-UK1(a), which was highly divergent from human astro-
virus (HAstV 1–8) genotypes, but closely related to VA1/HMO-C astroviruses, including one recovered from a case of
fatal encephalitis in an immunosuppressed child. The virus was detected in stool and serum, with highest levels in brain
and cerebrospinal ﬂuid (CSF). Immunohistochemistry of the brain biopsy showed positive neuronal staining. A survey of
680 stool and 349 CSF samples identiﬁed a related virus in the stool of another immunosuppressed child.
Conclusions. The discovery of HAstV-VA1/HMO-C-UK1(a) as the cause of encephalitis in this case provides fur-
ther evidence that VA1/HMO-C viruses, unlike HAstV 1–8, are neuropathic, particularly in immunocompromised pa-
tients, and should be considered in the differential diagnosis of encephalopathy. With a turnaround from sample receipt
to result of <1 week, we conﬁrm that RNA-Seq presents a valuable diagnostic tool in unexplained encephalitis.
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Encephalitis is characterized by inﬂammation in the
brain parenchyma associated with clinical evidence of
brain dysfunction [1, 2]. The majority of encephalitis
cases are thought to be viral in origin; however, in up
to 63% of cases a causative agent is not found [3].
Cases with unknown etiology pose difﬁculties in patient
management, particularly when a patient is immuno-
suppressed, because the treatment for infectious and
noninfectious cases differs greatly, with the latter some-
times requiring additional immunosuppression, which
can be detrimental if a pathogen is present.
To investigate a case of encephalopathy in an immu-
nosuppressed 18-month-old boy for which no cause
could be found by traditional techniques, we applied
RNA sequencing technologies to a brain biopsy. Deep
sequencing of the transcriptome has previously been
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used to identify viral ﬂora and disease-associated pathogens in
human tissues [4–8].A key feature of this methodology is that it
does not make prior assumptions about the type of pathogen,
but has the potential to detect RNA from all species.
Here we describe the use of this strategy in a routine diagnos-
tic setting to identify astrovirus (AstV) of the VA1 and human-
mink-ovine–like (HMO)-C subgroup as the likely causative
agent in this case. The result, which was obtained within 6 days
of brain biopsy, informed subsequent patient management. To
investigate further the need for routine diagnostic testing for
VA1/HMO-C viruses, we screened 680 samples of stool and
349 of cerebrospinal ﬂuid (CSF) from undiagnosed cases of
diarrhea and encephalitis, respectively. Our data underline the
clinical signiﬁcance of VA1/HMO-C AstV as a clinically signiﬁ-
cant pathogen in immunocompromised patients.
METHODS
Patient and Samples
Patient A, an 18-month-old boy with cartilage hair hypoplasia
and associated immunodeﬁciency due to RMRP mutations, un-
derwent a peripheral blood stem cell transplant on 28 March
2013 from a 10/10 human leukocyte antigen–matched unrelat-
ed donor following conditioning with ﬂudarabine (150 mg/m2
over 5 days), melphalan (140 mg/m2 day –2), and alemtuzumab
(1 mg/kg over 5 days) for in vivo T-cell depletion. Ciclosporin A
and mycophenolate mofetil were given as graft-vs-host disease
(GVHD) prophylaxis.
Transplant was uncomplicated with neutrophil engraftment
achieved by day 13. Persistent stool viruses (sapovirus, adenovi-
rus) were detected by polymerase chain reaction (PCR). Adeno-
viremia occurred from day 18 onward with peak load of 201 697
copies/mL on day 21. This required treatment with cidofovir
(5mg/kg 1 dose) and donor-derived adenovirus-speciﬁc cytotoxic
T-lymphocytes (1 × 104/kg total CD3+ cells) on day 28. Adeno-
virus load declined to 820 copies/mL 12 days after infusion (Sup-
plementary Figure 1). Two weeks later, the child became acutely
unwell with irritability, dystonia, and reduced consciousness. En-
cephalopathy secondary to drug toxicity, infectious complications,
or inﬂammation associated with immune reconstitution were
considered in the differential diagnosis. Ciclosporin was stopped
on day 43 and replaced bymethylprednisolone therapy (1 mg/kg).
Magnetic resonance imaging of the brain showed progressive
changes with loss of volume (Supplementary Figure 2), and
electroencephalography revealed increased amplitudes of ongo-
ing slow activity over posterior regions with no focal features or
epileptiform abnormalities. PCR of CSF 2 days, 2 weeks, and 1
month after onset of symptoms did not detect adenovirus, her-
pes simplex virus type 1 or 2, varicella zoster virus, cytomega-
lovirus, Epstein-Barr virus, BK virus, norovirus, sapovirus,
astrovirus (HAstV 1–8), rotavirus, enterovirus, measles,
parechovirus, JC virus, human herpesvirus type 6 or 7, or Toxo-
plasma. Brain biopsy performed 8 weeks after neurological de-
terioration was also negative for these pathogens as well as 18S
(fungal) and 16S (bacterial) ribosomal RNA gene PCR assays.
Histological examination of the brain (described below) showed
an unusual pattern of pathology, but the differential diagnosis
included encephalitis of infectious etiology. Withdrawal of im-
munosuppression was associated with the development of skin
GVHD (grade 2, stage 3) requiring methylprednisolone (2 mg/
kg/day). As a result, kinetics of T-cell reconstitution were re-
duced with a CD3 count of 0.35 × 109/L at 6 months, and in
the context of ongoing neurological impairment with recurrent
respiratory and gastrointestinal complications, the patient died
9 months after transplant.
Deep Sequencing
Total RNA was puriﬁed from a fresh brain biopsy and polyA
RNA separated for sequencing library preparation. Rapid
RNA-Seq was performed on an Illumina Miseq. Nonhost
data, assembled into contigs, and remaining nonassembled
reads that showed only partial homology to protein database se-
quences using BLASTx were analyzed using a Bayesian mixture
model [9] to obtain a concise summary of the species present in
the mixture. This approach overcomes the limitation of existing
methods for analysis of short read data, which are not designed
to detect pathogens at low levels. In this context, we use a Monte
Carlo Markov chain (MCMC) strategy to identify the subset of
species that best explains the data. Multiple MCMC chains are
run in parallel using a population MCMC strategy to speed up
convergence. Each potential species is then assigned a posterior
probability that quantiﬁes the support for the presence of this
infectious agent.
Pan-Astrovirus PCR and Sequencing
To conﬁrm the presence of AstV in the brain biopsy, a pan-
astrovirus heminested PCR assay was carried out as described
previously [10].
PCR products were capillary sequenced using BigDye 3.1 (Life
Technologies) and an ABI 3130. Sequencing data was visualized
and analyzed with SeqMan Pro version 11.1 (DNA Star). The
consensus sequence was checked for similarity to known AstV
sequences using BLASTn [11].
Real-time Reverse Transcription PCR
Contig sequences generated from deep sequencing were used to
design a real-time reverse transcription PCR assay speciﬁc to
the AstV identiﬁed in this study, named AstV-contig. Primers
are shown in Supplementary Table 1.
An AstV-contig PCR assay was used to retrospectively test all
stored samples for patient A during his hospital admission.
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These samples were from stool (n = 17), nasopharyngeal aspi-
rate (NPA) (n = 12), urine (n = 1), sera (n = 2), and CSF (n = 3).
To investigate the possible source of infection, all stored spec-
imens from patients on the same ward as patient A, which were
collected from 2 weeks before to 2 weeks after patient A’s ﬁrst
positive AstV-contig PCR result, were tested by the AstV-contig
PCR assay. This included 18 samples (14 stool and 4 urine)
from 9 patients. For patient B, who had a single positive stool
sample, an additional 14 stools, 23 NPAs, and 3 sera were tested
by the AstV-contig PCR.
Genome Sequencing
Twelve tiled primer sets were designed to cover the full AstV
genome. They were designed using the full genome sequences
for AstV-VA1 and -SG and partial sequences for HMO-C
(genbank accession numbers FJ973620, GQ891990, GQ415662,
GQ441191, GQ441192), as these showed 95%–98% identity with
the pan-astrovirus PCR product from the brain biopsy. Primer se-
quences are shown in Supplementary Table 1. The terminal 3′ end
of the genome was obtained by rapid ampliﬁcation of complemen-
tary DNA (cDNA) ends (RACE, Invitrogen).
The consensus sequence was checked for similarity to known
AstV sequences using BLAST and used for phylogenetic
analysis.
Phylogenetic Analysis
Clustal W was used to align a 432 nucleotide region of the
RNA-dependent RNA polymerase (RdRp) and 2460 nucleo-
tide region of the capsid gene with 39 other AstV sequences.
Sequences included representatives of the classical human
astroviruses HAstV1–8, bat, mink, ovine, and, to our knowl-
edge, all of the recently described novel HAstVs MLB-1–3,
HMO-A–C, VA-1–4, and -SG. Turkey AstV was used as an out-
group. The aligned regions correspond to nucleotides 3432–
3864 and 3628–4042 for the RdRp alignment and 4382–6733
and 4210–6486 for the capsid of AstV-SG and HAstV-1,
respectively.
The RdRp phylogenetic tree was reconstructed using the
neighbor-joining method [12] with 1000 bootstrap replicates
[13]. The evolutionary distances were computed using the max-
imum composite likelihood method [14] and are in units of the
number of base substitutions per site. All positions containing
gaps and missing data were eliminated. Evolutionary analyses
were conducted in MEGA5 [15].
Immunohistochemistry
Sections of the brain biopsy were stained using AstV-speciﬁc
antibody as used previously [16], kindly provided by Professor
Ian Lipkin. The immunohistochemistry was performed using a
titer of 1:1000 on a Leica Bond Max automated system stained
with antigen retrieval solution 2, for 10 minutes.
Epidemiology
To determine the local prevalence of AstV VA1/HMO-C, we
tested 686 stool and 349 CSF samples from immunocompetent
and immunocompromised patients. Stool samples were collect-
ed December 2013–February 2014 and CSF samples from Sep-
tember 2013 to March 2014. Samples were screened using the
AstV-contig PCR assay and a second, more broad-range
assay, VA1-ORF1. Primer and probe sequences are in Supple-
mentary Table 1.
RESULTS
Deep Sequencing
The RNA-Seq data consisted of 20 588 062 paired-end reads, of
which 92% passed quality control (nonrepetitive sequence and
average Phred scaled quality score >15) (Table 1). Reads that
could not be assigned to the human genome (77 915 reads,
0.4% of total reads) were potentially of foreign origin. Our mix-
ture model identiﬁed 2 viruses with conﬁdence, 1 of which was
the phiX bacteriophage (79% of nonhost reads) that was used
for quality control of the Illumina high-throughput sequencing.
Five assembled contigs (44 reads) and 2 nonassembled reads
(therefore 46 reads overall) were assigned to the AstV VA1
sequence (genbank accession number FJ973620) with 97%
sequence identity and a probability score of 1. After adding
the AstV VA1 and the bacteriophage phiX species in our mix-
ture model, we found no evidence for any additional viruses in
the data.
In addition to viral sequences, 0.6% (<500 reads) of the non-
host reads were assigned to environmental bacterial species.
A fraction (0.3%) of the remaining reads was assigned to
human sequences initially absent from our sequence database.
The remainder (20%) of the nonhuman data did not match any
Table 1. Deep-Sequencing Read Data
Data
Read
Count
Total
Reads
Nonhuman
Reads
Raw data 20 588 062 100%
Quality control passed data 18 877 676 91.69%
Nonhuman data 77 915 0.38%
PhiX control 61 758 0.3% 79%
Astrovirus 46 0.0002% 0.06%
Environmental bacteriaa 470 0.002% 0.6%
Unidentified 15 377 0.07% 20%
Humanb 264 0.001% 0.3%
aSphingobium yanoikuyae, Afipia broomeae, Roseomonas cervicalis, Massilia
timonae, Achromobacter piechaudii, Acinetobacter species, Serratia odorifera,
Citrobacter youngae, Escherichia coli, Propionibacterium acnes, Sphingobac-
terium spiritivorum, Streptococcus mitis.
bReads that were not filtered out at the nucleotide level (BLASTn) but identified
at the amino acid level (BLASTx).
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database sequence reliably, which could result from sequencing
errors or species without homology to known sequences
(Table 1).
The AstV assigned contigs range from 167 to 471 bp in
length. On the amino acid level, the percentage identity they
share with AstV-VA1 viral proteins is 96%–100%. The contigs
were mapped with BLASTn against the genome of AstV VA1,
showing that the reads map to the 5′ and 3′ ends of the viral
genome (Supplementary Figure 3A). The assembled contigs
map equally well to the 3′ and 5′ ends of AstV-SG and the 3′
end of HMO-C (genbank accession numbers GQ891990 and
GQ415662). We have named the AstV identiﬁed in this study
HAstV-VA1/HMO-C-UK1(a).
Full Genome Analysis and Phylogeny
Phylogenetic analysis of the RdRp gene places HAstV-VA1/
HMO-C-UK1(a) in a cluster with HMO-C, -VA1, and -SG
(Figure 1) with 98%, 97%, and 95% nucleotide sequence iden-
tity, respectively (Supplementary Figure 4A). This group of
viruses is more closely related to mink and ovine AstV sequenc-
es than HAstV 1–8. The phylogenetic relationship between
HAstV-VA1/HMO-C-UK1(a) and other AstVs is unchanged
when analyzing RdRp, capsid, or full genome (Figure 1 and
Supplementary Figure 4; phylogenies for capsid and full ge-
nome not shown), suggesting that recombination with other
known strains has not occurred.
The 6563 nucleotide (excluding the 5′ untranslated region)
HAstV-VA1/HMO-C-UK1(a) genome (GenBank accession
number KJ920196) has 95% sequence identity with AstV-SG
(Supplementary Figure 4B), which has previously been de-
scribed in a fatal case of encephalitis in an immunosuppressed
patient [16]. Conversely, the percentage sequence identity of
HAstV-VA1/HMO-C-UK1(a) and classical human astrovirus
(HAstV-1), normally associated with diarrhea, is <47%.
Conﬁrmation by PCR
cDNA from the brain biopsy was positive by pan-astrovirus and
both real-time PCR assays, conﬁrming the presence of AstV in
the brain tissue. A 560-bp amplicon generated by the former
showed 95%, 97%, and 98% identity to AstVs SG, VA1, and
HMO-C, respectively. The results of the real-time astrovirus
PCR on 35 stored samples from patient A show the highest
viral titer (cycle threshold [Ct] 25) in the brain biopsy, consis-
tently positive CSF, and intermittently positive stool and serum
(Figure 2 and Supplementary Table 2).
Histopathology
Routine histopathology investigations of the brain biopsy
showed frequent neuronal apoptosis demonstrated by neuronal
karyorrhexis (Figure 3A). There was microglial activation con-
ﬁrmed on CD68 immunohistochemistry (Figure 3B). There was
diffuse activation of microglial but also small clusters, some
of which were associated with neurons, and occasional areas
suggestive of neuronophagia were seen. However, lymphocytes
were inconspicuous on microscopy and immunohistochemis-
try (Figure 3C), and there were no acute inﬂammatory cells.
Extensive astrocytosis (Figure 3D) was conﬁrmed on glial ﬁbril-
lary acidic protein immunohistochemistry.
Electron microscopy showed frequent microglial activation
and microglial surrounding neurons. Many neurons appeared
shrunken and electron-dense. Viral material was not seen, but
a rare focus of crystalline material was found in neurons
(Figure 3F).
Immunohistochemistry
Immunohistochemistry for AstV was positive, staining cell bod-
ies and processes within the neuropil (Figure 3E). Several of the
positive cells had the morphology of pyramidal neurons.
qPCR Screening Within the Ward
Results for screening of patients from the same ward identiﬁed 1
(1/14) positive stool sample (Ct 38; Supplementary Table 3)
from a single patient (patient B), collected 1 week after patient
A was admitted and 2 weeks before patient A’s ﬁrst positive
sample. There was insufﬁcient residual sample for repeat testing
by quantitative PCR or for sequencing; therefore, the positive
result could not be conﬁrmed. No other stored samples from
patient B were positive.
qPCR Screening Within Local and Other Hospitals
Wider screening identiﬁed 1 (1/686) positive stool and no (0/
349) positive CSFs (Supplementary Table 3). The single positive
stool came from an immunosuppressed child, patient C, with
diarrhea. The full genome, HAstV-VA1/HMO-C-UK1(b) (gen-
bank accession number KJ920197), was sequenced by primer
walking and included in the phylogenetic analysis (Figure 1
and Supplementary Figure 4). HAstV-VA1/HMO-C-UK1(b)
had 99.4% identity to HAstV-VA1/HMO-C-UK1(a).
DISCUSSION
Encephalopathy occurring in immunodeﬁcient subjects or re-
cipients of stem cell transplants can present a diagnostic dilem-
ma; distinguishing infection from other potential causes such as
drug toxicity or GVHD can be difﬁcult. In the case outlined
here of encephalitis occurring in an immunosuppressed 18-
month-old boy, having excluded common pathogens using
conventional methods, we resorted to deep sequencing of
brain tissue from which we were able to identify astrovirus,
HAstV-VA1/HMO-C-UK1(a). Based on phylogeny, we propose
that this virus belongs to the VA1 and HMO-C group of astro-
viruses. VA1/HMO-C astroviruses are part of a divergent group
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Figure 1. Phylogenetic relationship of human astrovirus (HAstV)–VA1/HMO-C-UK1(a) ( ) and -UK1(b) ( ) to other astroviruses (AstVs) based on
RNA-dependent RNA polymerase nucleotide sequences. indicates other AstV species that have been reported in patients with neurological disease.
indicates sequences of animal origin, not human. Scale bar represents the number of base substitutions per site. Abbreviations: BAstV, bat astrovirus;
MAstV, mink astrovirus; OAstV, ovine astrovirus; TAstV, turkey astrovirus.
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that is related to Astroviridae found in association with neuro-
logical illnesses in mink [17] and cattle [18]. Our ﬁnding re-
presents the second report of an AstV in the VA1/HMO-C
group causing fatal encephalitis, which conﬁrms a pathogenic
role for this virus group likely to have been previously underre-
cognized in immunocompromised patients. The ﬁrst case
described, AstV-SG, is phylogenetically close to HAstV-VA1/
HMO-C-UK1(a) and was also found by deep sequencing of
brain tissue from a 15-year-old boy with X-linked agammaglob-
ulinemia who developed unexplained encephalitis [16]. Two
more distantly related viruses in this phylum, HMO-A and
-B, were detected in stool from children with nonpolio ﬂaccid
paralysis; however, healthy controls were not included in the
study, so the clinical signiﬁcance of HMO-A and -B is unclear.
Other related HMO-C viruses have been associated with diar-
rhea in children living in Nepal [10] and the United States
[19], suggesting a global distribution of this virus.
The neuropathology on brain biopsy was distinctive with fre-
quent neuronal apoptosis associated with a microglial reaction
but lacking a signiﬁcant lymphocytic inﬂammatory response.
Whereas the pattern of microglial reaction raised the possibility
of viral encephalitis, the pattern of neuronal cell death would be
unusual in most typical viral encephalitides.
The pattern of both gastrointestinal and neurological infec-
tions caused by VA1/HMO-C viruses contrasts with that of con-
ventional human Astroviridae, HAstV 1–8, which are primarily
associated with gastroenteritis. For HAstV-VA1/HMO-C-UK1
(a), RNA in the brain was conﬁrmed by 3 different PCR assays
and we were able to generate full-genome sequences using
overlapping PCR. The positive immunohistochemistry for the
capsid protein provided further conﬁrmation of replication
competent virus in the brain. The highest titers of viral RNA
were found in the brain tissue, and RNA was consistently de-
tected in the CSF. Signiﬁcantly lower levels of viral RNA
were found in stool and serum (plasma and whole blood
were not available), the latter conﬁrming viremic spread. By
contrast, 1 case of HAstV-4 has been identiﬁed in brain tissue
from a patient with severe combined immunodeﬁciency
Figure 2. A, AstV-contig polymerase chain reaction results for all retrospectively tested samples from patient A. Data points at the base of the y-axis indicate
astrovirus (HAstV)–VA1/HMO-C-UK1(a) RNA not detected. Cycle threshold (Ct) values represent the cycle number at which ampliﬁcation was detected and thus
have an inverse relationship with viral titer; a smaller Ct value indicates a higher titer. In clinical practice, Ct >38 may be considered equivocal but, in the context
of other positive results, is considered a true positive. A difference of 3 Ct values is approximately equivalent to a 10-fold difference in viral load. B, Clinical and
diagnostic timeline. Abbreviations: AstV, astrovirus; CSF, cerebrospinal ﬂuid; HAstV, human astrovirus; NPA, nasopharyngeal aspirate.
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following a hematopoietic stem cell transplant [20]; however,
this was associated with much higher levels of viral RNA in
the stool, signiﬁcantly lower levels in the brain, and no immu-
nohistochemical evidence of viral proteins in brain, although
intestinal staining was positive.
A cross-sectional community study of diarrhea identiﬁed
HMO-C viruses in 2% of cases of diarrhea and 1% of controls,
compared with 13% of cases due to HAstV [10]. This low prev-
alence ﬁts with data from our study of 680 stool and 349 CSF
samples from all ages that identiﬁed only 2 patients (patients
B and C), both immunocompromised, with evidence of the
virus in the stool. In patient B, the infection may have been tran-
sient or even caused by contamination, as the viral load was at
the limit of detection of the assay and none of 42 (16 stool, 3
serum, 23 NPA) additional samples from the child were posi-
tive. Whole-genome sequencing of the AstV from the second
patient, patient C, which we have termed HAstV-VA1/HMO-
C-UK1(b), revealed it to be 99.4% similar to patient A’s virus,
which is phylogenetically closer than has been observed for
other co-circulating VA1/HMO-C viruses . The result suggests
that transmission may have occurred between patients A and
C, although without additional sequences from the United
Kingdom this cannot be conﬁrmed. Because infection in patients
A and C occurred many months apart and they were never
together on the same ward, transmission, if it occurred, is likely
to have been indirect. Similar to HAstV 1–8, antibodies against
HMO-C viruses have been shown to increase with age, reach-
ing a prevalence of 65% in adults in the United States [21].
Taken together, these data suggest that in healthy individuals,
VA1/HMO-C AstV infection is common but generally asymp-
tomatic. By contrast, our data support VA1/HMO-C as a neuro-
pathic agent in immunocompromised patients and one that
should be looked for in cases of encephalitis.
In summary, we have used state-of-the-art deep sequencing
in a routine diagnostic setting together with PCR and immuno-
histochemistry to identify AstV VA1/HMO-C as the cause of
encephalitis of unknown origin occurring in an immunocompro-
mised child and a possible case of nosocomial spread. We have
used deep-sequencing methodologies in a diagnostic setting to
identify the causative agent in unknown encephalitis within 6
days of receiving the specimen. The result excluded drug toxicity
and immune-mediated inﬂammation as causes for the clinical
picture, and informed a decision to reduce immunosuppression.
This case illustrates the utility of deep sequencing in a clinical set-
ting to identify unexpected or novel pathogens.
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